Study of drug combination therapy in asymptomatic patients with frequent premature ventricular contractions and normal heart function to prevent left ventricular dysfunction

3 1 1 1

What is this study about?

This study focuses on patients with premature ventricular complexes (PVCs), which are extra, abnormal heartbeats that begin in the heart’s lower chambers. The study specifically looks at people who have frequent PVCs (more than 10% of total heartbeats) but don’t feel any symptoms and have normal heart function. Several medications will be tested including verapamil, nebivolol, amiodarone, propafenone, bisoprolol, diltiazem, flecainide, and sotalol.

The purpose is to determine if treating patients who have frequent PVCs but no symptoms can prevent future heart problems better than simply monitoring them without treatment. The study will last for 24 months, during which patients may receive medication or, if necessary, a procedure called ablation (which uses heat to destroy small areas of heart tissue causing irregular rhythms) if medications alone don’t reduce the PVCs enough.

Throughout the study, doctors will monitor how well the heart is pumping blood using special imaging tests like cardiac magnetic resonance imaging (cMRI) or heart ultrasound. They will also track changes in heart function, measure exercise capacity, and monitor for any side effects from the treatments.

1 Initial evaluation

Your heart function will be evaluated using cardiac magnetic resonance imaging (cMRI) or heart ultrasound if cMRI is not possible

You will complete a quality of life questionnaire called SF-36

Your exercise capacity will be tested on a treadmill

A blood test will be performed to measure Nt-ProBNP (a heart function marker)

2 Treatment assignment

You will be assigned to either receive medication treatment or no treatment (regular monitoring only)

If assigned to the medication group, treatment will begin with oral heart rhythm medications (antiarrhythmic drugs)

The medications may include: verapamil, amiodarone, propafenone, bisoprolol, cimetidine, flecainide, or sotalol

3 Follow-up visits

You will have check-ups at 6, 12, 18, and 24 months

During each visit, your heart rhythm will be monitored to measure PVC burden (extra heartbeats)

At 12 months, you will complete another SF-36 quality of life questionnaire

If you are receiving medication and your PVC burden remains above 10% after trying two different medications, additional treatment options may be discussed

4 Final evaluation

At 24 months, you will have a final heart evaluation with cMRI or heart ultrasound

Your exercise capacity will be tested again on the treadmill

A final blood test for Nt-ProBNP will be performed

You will complete a final SF-36 quality of life questionnaire

Who Can Join the Study?

  • Age between 18 and 85 years old
  • Have frequent irregular heartbeats (PVCs) that occur in at least 10% of all heartbeats, regardless of whether you are currently taking heart rhythm medications
  • Have no symptoms related to the irregular heartbeats
  • Have normal heart function (left ventricular ejection fraction of 55% or higher). You can participate even if you have an underlying heart condition, as long as your heart pumping function remains normal
  • Must be able to understand and sign an informed consent form
  • Can be either male or female

Who Cannot Join the Study?

  • Age below 18 years or above 75 years
  • Presence of any symptoms related to heart rhythm disturbances (such as palpitations, dizziness, fainting)
  • Left ventricular ejection fraction (a measure of heart’s pumping ability) less than normal
  • Previous treatment with antiarrhythmic drugs (medications that control heart rhythm) or ablation procedure
  • Pregnancy or planning to become pregnant during the study period
  • Having less than 10% of premature ventricular contractions (extra heartbeats originating from the lower chambers of the heart)
  • Presence of other significant heart conditions
  • Participation in other clinical trials
  • Inability to provide informed consent
  • Known allergies to medications used in the study
  • Severe kidney or liver disease that could affect medication metabolism
  • History of substance abuse that could interfere with study participation
  • Mental conditions that could affect ability to follow study requirements

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Centre Jean Perrin Clermont Ferrand France
Clinique Pasteur Toulouse France
Centre Hospitalier Universitaire De Bordeaux Bordeaux France
Centre Hospitalier Regional Et Universitaire De Brest Brest France
Oncopole Claudius Regaud Toulouse France
CHU Grenoble Alpes La Tronche France

Other Sites

Site Name City Country Status
Centre Hospitalier Universitaire Rouen Rouen France
Centre Hospitalier Groupe Hospitalier De La Rochelle Re Aunis La Rochelle France
Centre Hospitalier Du Pays D Aix Centre Hospitalier Intercommunal Aix-Pertuis Aix En Provence France
Ramsay Generale De Sante Bayonne France
Centre Hospitalier Universitaire De Montpellier Montpellier France
Centre Hospitalier Universitaire De Nantes Nantes France
Hopital Saint Joseph Marseille France
Hopital NOVO Pontoise France
Centre Hospitalier Universitaire De Rennes Rennes France
Hopital Prive Clairval Marseille France
Hopital Beaujon Clichy France
Iaqwvlym Mcyjobvqmm Moshfvzzfq Paris France
Ckcxom Hlprfzpxobv Iiqfdqupclacm Ll Ryuotcxqchxrfakkz Monfermeil France
Cufbmd Hjrrdhmukut Urpmirjwfbjgw Dj Dcrvg Dijon France
Abbwnqrsml Pnntryuq Hkwtmkqf De Msptqmaiy Marseille France
Bghognww Uymplemzwo Hwtdgufu Chfjcx Besançon France
Cusigu Hhiiuankjxq Rpguhjxg Uutgvqbahhhwe Do Tlirs Tours France
Cnfv Dx Nvcje Vandoeuvre Les Nancy France
Hfnvmty Jkqcjx Cbdsiyi Mhump Massy France
Ibtlbmxv dv Cpiqigyeydjb Heoemdwktey Ucgokdrandpai dm Slraz Evyulzd (ccgfzgz Saint Priest En Jarez France
Hdpmqljs Uqlxsifvjercnc Sttxyycoex &hfwqpd Hntzsev dp Hzzynutwnqj STRASBOURG, Alsace France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Recruiting
07.10.2024

Trial locations

Based on the provided trial information, the medications and therapies involved are:

Antiarrhythmic Drugs (AADs)
These are medications used to control and reduce premature ventricular complexes (PVCs), which are a type of irregular heartbeat. They help maintain normal heart rhythm and prevent heart rhythm disorders.

Catheter Ablation
This is not a medication but a medical procedure where small areas of heart tissue that are causing irregular heartbeats are destroyed using heat energy delivered through special catheters. In this trial, it’s used as a secondary treatment option when medications don’t sufficiently reduce PVCs.

Note: The specific antiarrhythmic drugs are not named in the source data, but the trial mentions using up to two different lines of antiarrhythmic drug treatment before considering ablation.

Premature Ventricular Contractions (PVCs) – A condition where extra, abnormal heartbeats originate from the heart’s lower chambers (ventricles), disrupting the normal heart rhythm. These extra beats occur earlier than the normal heartbeat sequence, causing a feeling of a skipped or fluttering heartbeat. PVCs can occur in people with otherwise normal hearts, ranging from occasional single beats to frequent episodes making up a significant percentage of total daily heartbeats. When frequent (more than 10% of total heartbeats), PVCs may lead to changes in the heart’s function over time.

Left Ventricular Dysfunction – A condition where the heart’s main pumping chamber (left ventricle) becomes less efficient at pumping blood to the body. The condition develops gradually as the heart muscle weakens or becomes less flexible. This results in a decreased ejection fraction, which is the percentage of blood pumped out with each heartbeat. The heart may enlarge as it tries to compensate for reduced pumping efficiency.

Trial ID:
2024-516372-14-00
Protocol code:
APHP180618
NCT ID:
NCT05784051
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • Comparison of Carvedilol and Flecainide Treatment in Patients with Idiopathic Ventricular Arrhythmias

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain